↓ Skip to main content

Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events

Overview of attention for article published in Hepatology, September 2009
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (69th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (54th percentile)

Mentioned by

twitter
1 X user
wikipedia
1 Wikipedia page
f1000
1 research highlight platform

Citations

dimensions_citation
226 Dimensions

Readers on

mendeley
97 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events
Published in
Hepatology, September 2009
DOI 10.1002/hep.23317
Pubmed ID
Authors

Craig Lammert, Einar Bjornsson, Anna Niklasson, Naga Chalasani

Abstract

Reactive metabolites generated by hepatic metabolism are thought to play an important role in the pathogenesis of drug-induced liver injury (DILI), but supporting data are limited. If this is true, then compounds with significant hepatic metabolism should cause more DILI than those without it. We conducted a study to examine the relationship between hepatic metabolism and DILI of prescription medications. We systematically extracted the metabolism characteristics of 207 of the most widely prescribed oral medications in the United States. Compounds with >50% hepatic metabolism were characterized as those with significant hepatic metabolism (n = 149). Hepatic adverse events of interest were alanine aminotransferase >3 times the upper limit of normal, jaundice, liver failure, liver transplantation, or fatal DILI. Compared with compounds with lesser hepatic metabolism, compounds belonging to the significant hepatic metabolism group had significantly higher frequency of alanine aminotransferase >3 times the upper limit of normal (35% versus 11%, P = 0.001), liver failure (28% versus 9%, P = 0.004), and fatal DILI (23% versus 4%, P = 0.001), but not jaundice (46% versus 35%, P = 0.2) or liver transplantation (9% versus 2%, P = 0.11). Twelve compounds with no hepatic metabolism had no reports of liver failure, liver transplantation, or fatal DILI. When the relationship between hepatic adverse events and combination of hepatic metabolism and daily dose was examined, compounds with both significant hepatic metabolism and daily dose >50 mg (n = 50) were significantly more hepatotoxic than compounds belonging to other groups. Compared with medications without biliary excretion, compounds with biliary excretion (n = 50) had significantly higher frequency of jaundice (74% versus 40%, P = 0.0001).

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 97 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Sweden 1 1%
Unknown 96 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 19 20%
Student > Bachelor 12 12%
Student > Master 11 11%
Researcher 10 10%
Student > Doctoral Student 6 6%
Other 22 23%
Unknown 17 18%
Readers by discipline Count As %
Medicine and Dentistry 23 24%
Pharmacology, Toxicology and Pharmaceutical Science 19 20%
Agricultural and Biological Sciences 17 18%
Biochemistry, Genetics and Molecular Biology 5 5%
Chemistry 4 4%
Other 10 10%
Unknown 19 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 June 2022.
All research outputs
#6,754,462
of 25,374,917 outputs
Outputs from Hepatology
#3,311
of 9,093 outputs
Outputs of similar age
#30,979
of 105,154 outputs
Outputs of similar age from Hepatology
#40
of 87 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 9,093 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.4. This one has gotten more attention than average, scoring higher than 63% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 105,154 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.
We're also able to compare this research output to 87 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 54% of its contemporaries.